AI Article Synopsis
- The study aimed to assess the lipoprotein profile and sex hormones in men with prostate cancer (PCa) compared to those with benign prostatic hyperplasia (BPH) and healthy controls, looking for links to inflammation.
- A total of 150 men aged 50-65 were analyzed across three groups based on prostate health, measuring cholesterol levels, testosterone, estradiol, and other markers.
- Results indicated that PCa patients had higher triglyceride to HDL cholesterol ratios and lower HDL cholesterol, along with increased androgen levels and reduced adiponectin compared to controls and BPH patients.
Article Abstract
Objective: To evaluate lipoprotein profile and sex hormones in patients with prostate cancer (PCa) and benign prostatic hyperplasia (BPH) and their possible associations with some inflammatory markers linked to PCa.
Methods: A total of 150 men (50-65 years), matched by age and body mass index (BMI), included in this study and divided into three groups according to total prostate specific antigen (PSA), digital rectal examination and prostate biopsy: 50 PCa, 50 BPH and 50 controls. Total cholesterol (Chol), HDL-chol, LDL-chol, triglycerides (TG), total testosterone (T), free T (FT), bioavailable T (BioT), estradiol and SHBG were measured. The free androgen index (FAI) and TG/HDL-chol were calculated. In 25 PCa and 25 controls, C-reactive protein (hs-CRP), adiponectin and insulin were determined.
Results: Patients with PCa showed higher TG/HDL-chol and diminished HDL-chol than Controls and BPH. PSA correlated inversely with HDL-chol and directly with TG/HDL-chol. FAI, FT, BioT and estradiol levels were higher, and SHBG and adiponectin were lower in PCa than in Controls. No differences were found in androgens between BPH and PCa.
Conclusion: Our most novel findings are that the patients with PCa presented lower total Chol and HDL-chol and higher TG/HDL-chol than BPH and Controls. Patients with PCa showed higher androgens and lower adiponectin than Controls.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/13685530903410617 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The integration of conventional omics data such as genomics and transcriptomics data into artificial intelligence models has advanced significantly in recent years; however, their low applicability in clinical contexts, due to the high complexity of models, has been limited in their direct use inpatients. We integrated classic omics, including DNA mutation and RNA gene expression, added a novel focus on promising omics methods based on A>I(G) RNA editing, and developed a drug response prediction model. We analyzed 104 patients from the Breast Cancer Genome-Guided Therapy Study (NCT02022202).
View Article and Find Full Text PDFEffect of Enhanced Recovery after Surgery Concept Combined with Roy's Adaptation Model on Perioperative Mental Health, Quality of Life, Recovery Conditions, and Postoperative Complications in Patients Undergoing Radical Prostatectomy: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Urology, Affiliated Hospital of Southwest Medical University, 646000 Luzhou, Sichuan, China.
Background: Prostate cancer (PCa) is a common malignant tumour in males, with radical prostatectomy (RP) being the typical treatment. The concept of enhanced recovery after surgery (ERAS) and Roy's adaptation model (RAM) have been proved effective and reliable nursing methods in clinical practice. However, the combined effect of these two methods on patients undergoing RP remains unclear.
View Article and Find Full Text PDFEHMT2-mediated R-loop formation promotes the malignant progression of prostate cancer via activating Aurora B.
Clin Transl Med
January 2025
Department of Urology, The Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu, China.
Background: Chromosomal instability (CIN), a hallmark of cancer, is commonly linked to poor prognosis in high-grade prostate cancer (PCa). Paradoxically, excessively high levels of CIN may impair cancer cell viability. Consequently, understanding how tumours adapt to CIN is critical for identifying novel therapeutic targets.
View Article and Find Full Text PDFCombined transrectal ultrasound and radiomics model for evaluating the therapeutic effects of neoadjuvant chemoradiotherapy in locally advanced rectal cancer.
Int J Colorectal Dis
January 2025
Department of Medical Ultrasound, West China Hospital of Sichuan University, 37# Guo Xue Xiang, Chengdu, 610041, Sichuan, China.
Purpose: This study aimed to explore a combined transrectal ultrasound (TRUS) and radiomics model for predicting tumor regression grade (TRG) after neoadjuvant chemoradiotherapy (NCRT) in patients with locally advanced rectal cancer (LARC).
Methods: Among 190 patients with LARC, 53 belonged to GRG and 137 to PRG. Eight TRUS parameters were identified as statistically significant (P < 0.
Tracing prostate cancer - the evolution of PET-CT applications.
Rep Pract Oncol Radiother
December 2024
Nuclear Medicine Department, Greater Poland Cancer Centre, Poznan, Poland.
Background: The study aimed to overview radiopharmaceuticals used for the nuclear medicine (NM) imaging of prostate cancer (Pca) since the first mentions in the literature up to recent reports, with the special focus on positron emission tomography-computed tomography (PET-CT) radiotracers.
Materials And Methods: We found over 3500 articles discussing the role of PET-CT in Pca patients' management published within 1990-2023. We summarized the past and present interests of the Authors when the Pca diagnostic imaging and the use of radiotracers in Pca diagnosis are considered.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!